NCT07382713 2026-02-03
Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT04517357 2025-02-24
A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT06541314 2024-11-27
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
Qilu Hospital of Shandong University
Phase 2 Recruiting
NCT06552858 2024-08-14
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Fudan University
Phase 2 Not yet recruiting
NCT06446206 2024-06-06
Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer
The First Hospital of Jilin University
Phase 2 Not yet recruiting
NCT06413992 2024-05-14
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06161272 2023-12-07
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Guangxi Medical University
Phase 2 Unknown
NCT06081595 2023-10-13
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
Fudan University
Phase 2 Not yet recruiting
NCT06063070 2023-10-02
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT05585281 2023-07-28
A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Liaoning Cancer Hospital & Institute
Phase 2 Unknown
NCT05170594 2021-12-28
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Unknown